Search
                    Arizona Paid Clinical Trials
A listing of 1697  clinical trials  in Arizona  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1273 - 1284 of 1697
        
                Arizona is currently home to 1697 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples With Implications for Alzheimer's Disease Risk
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to learn if the culturally adapted couples sleep health intervention (Nuestro Sueno) improves positive airway pressure use and sleep among Hispanic couples in which one partner was diagnosed with sleep apnea and starting positive airway pressure treatment.
The main questions are:
1. Does Nuestro sueno improve the patient's positive airway pressure use over the first 3 months of using it compared to an information control?
2. Does Nuestro sueno improve sleep q...  Read More             
        
        
    Gender:
                ALL
            Ages:
                35 years and above
            Trial Updated:
                03/27/2025
            
            Locations: Banner Health, Tucson, Arizona         
        
        
            Conditions: Sleep Apnea, Sleep Disturbance
        
            
        
    
                
                                    Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
                                
            
            
        Recruiting
                            
            
                The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion.
The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA) compared to placebo in decreasing 24-hour all-cause mortality in children with traumatic life threatening hemorrhage.             
        
        
    Gender:
                ALL
            Ages:
                17 years and below
            Trial Updated:
                03/27/2025
            
            Locations: University of Arizona, Tucson, Arizona         
        
        
            Conditions: Hemorrhagic Shock, Trauma Injury
        
            
        
    
                
                                    Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers
                                
            
            
        Recruiting
                            
            
                The purpose of this clinical trial is to evaluate the safety and effectiveness of the treatment with the COMS One device in subjects with refractory diabetic foot ulcers (DFUs). The prospective randomized, double-blinded, sham-controlled trial is designed to demonstrate superiority of wound closure of the COMS One device to a sham-control device through 24 weeks post-application, when each is administered in conjunction with standard of care (SOC) in the treatment of DFUs.             
        
        
    Gender:
                ALL
            Ages:
                Between 22 years and 90 years
            Trial Updated:
                03/27/2025
            
            Locations: Titan Clinical Research, Mesa, Arizona         
        
        
            Conditions: Diabetic Foot Ulcer
        
            
        
    
                
                                    An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
                                
            
            
        Recruiting
                            
            
                An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                03/26/2025
            
            Locations: Praxis Research Site, Phoenix, Arizona         
        
        
            Conditions: Focal Onset Seizure, Primary Generalized Epilepsy
        
            
        
    
                
                                    An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED)
                                
            
            
        Recruiting
                            
            
                This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                03/26/2025
            
            Locations: Scottsdale Clinical Trials, Scottsdale, Arizona         
        
        
            Conditions: Thyroid Eye Disease
        
            
        
    
                
                                    Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
                                
            
            
        Recruiting
                            
            
                This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins, as well as for cancer, hepatitis, and infections. There is previous evidence of significant tumor shrinkage occurring in the 2-month window between diagnosis and surgery in women who have taken TTM....  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                03/26/2025
            
            Locations: Mayo Clinic in Arizona, Scottsdale, Arizona         
        
        
            Conditions: Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
        
            
        
    
                
                                    SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
                                
            
            
        Recruiting
                            
            
                This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                03/26/2025
            
            Locations: AKDHC Bullhead City, Bullhead City, Arizona         
        
        
            Conditions: Chronic Kidney Diseases, End Stage Renal Disease, Arteriovenous Fistula, Hemodialysis Access Failure, ESRD, Vascular Access Complication, Renal Failure, Catheter Complications, Catheter Dysfunction, Renal Insufficiency
        
            
        
    
                
                                    SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
                                
            
            
        Recruiting
                            
            
                Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.             
        
        
    Gender:
                ALL
            Ages:
                Between 12 years and 100 years
            Trial Updated:
                03/26/2025
            
            Locations: Arizona Hemophilia and Thrombosis Center at Phoenix Children's Hospital, Phoenix, Arizona         
        
        
            Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
        
            
        
    
                
                                    ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
                                
            
            
        Recruiting
                            
            
                In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from...  Read More             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                03/26/2025
            
            Locations: Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital, Phoenix, Arizona         
        
        
            Conditions: Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
        
            
        
    
                
                                    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
                                
            
            
        Recruiting
                            
            
                To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 100 years
            Trial Updated:
                03/26/2025
            
            Locations: Arizona Oncology Associates Professional Corporation, Tucson, Arizona         
        
        
            Conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
        
            
        
    
                
                                    Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
                                
            
            
        Recruiting
                            
            
                HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant hypertension on three(3) or more antihypertensive medications             
        
        
    Gender:
                ALL
            Ages:
                Between 22 years and 80 years
            Trial Updated:
                03/25/2025
            
            Locations: University of Arizona Department of Urology, Tucson, Arizona         
        
        
            Conditions: Resistant Hypertension
        
            
        
    
                
                                    InfasurfAero™ Versus Sham Treatment in Preterm Newborns with RDS
                                
            
            
        Recruiting
                            
            
                The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.             
        
        
    Gender:
                ALL
            Ages:
                Between 29 weeks and 36 weeks
            Trial Updated:
                03/25/2025
            
            Locations: St. Josephs Hospital and Medical Center, Phoenix, Arizona         
        
        
            Conditions: Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
        
            
        
    